Selinexor for multiple myeloma.

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Australian Prescriber Pub Date : 2022-12-01 DOI:10.18773/austprescr.2022.072

引用次数: 0

Abstract

Exportin-1 is an essential nuclear exporter of many tumour suppressor proteins, growth regulator proteins and several classes of messenger RNAs, including those of oncogenic proteins. It is overexpressed in several cancers including multiple myeloma. Selinexor is a selective inhibitor of exportin-1. This inhibition leads to marked accumulation of the tumour suppressor proteins and growth regulator proteins in the nucleus and reduced expression of several oncoproteins, resulting in cell cycle arrest and apoptosis of cancer cells.

Abstract Image

查看原文本刊更多论文

Selinexor治疗多发性骨髓瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.